InfuSystems: More Upside Ahead

Shareholders Unite Investing Group Leader Follow Summary InfuSystems has shifted to a profit-focused strategy, driving a 24% FY25 adjusted EBITDA increase and maintaining strong margins despite GE contract restructuring. Wound Care revenue surged 154% due to partnerships and favorable reimbursement, while Oncology achieved record volumes and robust Patient Services growth. INFU's balance sheet remains conservative, with net debt at 0.61x EBITDA, $55.2M liquidity, and ongoing share repurchases reducing share count by 5% in H1. At 7.5x EV/EBITDA and 1.7x EV/S, valuation is reasonable; continued margin expansion and rapid growth in select segments support further upside. Looking for a portfolio of ideas like this one? Members of SHU Growth Portfolio get exclusive access to our subscriber-only portfolios. Learn More » Alexandr Lebedko/iStock via Getty Images InfuSystems ( INFU ) offers new and pre-owned infusion pumps and consumables to hospitals, oncology practices, ambulatory surgery centers, and home infusion providers, with flexible financing options. There's a simple reason why the stock is still very attractive: Last year, the company switched This article was written by Shareholders Unite 20.32K Followers Follow Shareholders Unite is a retired academic with 30+ years of experience in the financial markets. He looks to find small companies with multi-bagger potential while mitigating risks through a portfolio approach. He runs SHU Growth Portfolio where he offers wide coverage of several small companies with high growth possibilities. He has a buy and hold approach with tranche purchases of stocks of interest. The service features an illustrative portfolio to incorporate into your portfolio, buy alerts, weekend stock and market updates, and a chat room. Learn more Analyst’s Disclosure: I/we have a beneficial long position in the shares of INFU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.